Series
Most Recent Segment
What This Means
Featuring Ernexa Therapeutics
November 6, 2025
Sanjeev Luther, President and CEO of Ernexa, discusses the Company’s recently announced partnership agreement with Cellipont Bioservices focused on Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa’s lead cell therapy for the treatment of ovarian cancer, into clinical manufacturing and clinical trials.
What This Means
What This Means provides investors with context to press releases directly from company management teams. It also provides the opportunity for companies to communicate directly to investors and elaborate on recent key news and highlight value driving milestones.
CEO Connect
CEO Connect allows investors to hear directly from company CEOs, who will provide a brief presentation followed by an interactive Q&A session. Investors and interested parties have the opportunity to submit questions live during the event.
KOL Connect
KOL Connect features a moderated, in-depth discussion with members of the management team from participating companies along with Key Opinion Leaders.
What This Means
Featuring HCW Biologics
October 22, 2025
Dr. Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics, discusses the Company’s lead product candidate, known as HCW11-040, which is the Company’s franchise immunotherapeutic for internal clinical development as a second-generation immune checkpoint inhibitor.
What This Means
Featuring HCW Biologics
September 30, 2025
Dr. Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics discusses the Company’s recent news announcing its second-generation T-Cell Engager program. The Company has joined a small group of innovative biotechnology companies who have discovered new compounds that overcome resistance mechanisms and improve the ability to treat solid tumors.
What This Means
Featuring enVVeno Medical
September 26, 2025
Rob Berman, CEO discusses the Company’s recent news announcing it filed a request for supervisory appeal of the not-approvable letter from the Center for Devices and Radiological Health (CDRH) of the U.S. Food & Drug Administration (FDA) received on August 19, 2025, in response to its Premarket Approval (PMA) application for the VenoValve®, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI).
What This Means
Featuring Nuwellis, Inc.
September 17, 2025
Ryan Marthaler, Vice President of Product Marketing & Business Development of Nuwellis, discussed the Company’s recent news release announcing that the National Institutes of Health (NIH) has awarded an approximately $3 million multi-year grant to its development partner, Koronis Biomedical Technologies Corporation (KBT).
What This Means
Featuring Autonomix
September 4, 2025
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company’s recently announced longer-term post hoc analysis results from its proof-of-concept human clinical trial (“PoC 1”) which demonstrated sustained pain reduction, quality of life gains and 100% zero opioid use.
KOL Connect
Featuring Palisade Bio
August 25, 2025
Moderated discussion with leading expert in Fibrostenotic Crohn’s Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan
Segment provides further insight into the need for more effective treatment options for FSCD and how PALI-2108 may become a leader in the new frontier of IBD therapeutics
What This Means
Featuring Senti Biosciences
August 12, 2025
Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, discussed the Company’s recently announced recommended Phase 2 dose selection for its potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy, SENTI-202, in development for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML).
What This Means
Featuring Sonnet BioTherapeutics
August 11, 2025
Dr. Richard Kenney, Chief Medical Officer of Sonnet discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)
What This Means
Featuring enVVeno Medical
August 4, 2025
Rob Berman, CEO and Dr. Marc Glickman, CMO of enVVeno Medical discuss the progressive nature of chronic veinous insufficiency and whether President Trump may one day be a candidate for the VenoValve® following U.S. Food and Drug Administration (FDA) approval.
What This Means
Featuring GRI Bio
July 31, 2025
Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI, discusses the Company’s recently announced 6-week interim biomarker data from its ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis (“IPF”).
What This Means
Featuring Akari Therapeutics
July 29, 2025
Abizer Gaslightwala, President and CEO of Akari Therapeutics discusses Akari’s commitment to continued research to better understand the multiple effects of its novel spliceosome modulator, PH1.
CEO Connect
Featuring CNS Pharmaceuticals
July 09, 2025
John Climaco, CEO of CNS Pharmaceuticals provides an overview of CNSP’s lead program, TPI 287, and discusses key insights from his recent attendance at the Longwood Healthcare Leaders Spring 2025 Meeting in Cambridge, MA.
What This Means
Featuring Akari Therapeutics
June 26, 2025
Abizer Gaslightwala, President and CEO of Akari Therapeutics discusses the Company’s recently issued India Patent No. 562,919 titled, “Thailanstatin Analogs,” covering claims for its potent immuno-oncology PH1 payload, proprietary non-cleavable and cleavable linkers and ADC technology which has applications across various cancer targets.
KOL Connect
Featuring: CNS Pharmaceuticals
June 24, 2025
Dr. Erin Dunbar, a founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, discusses the patient journey and current treatment landscape for Glioblastoma Multiforme and CNS Pharma’s lead product candidate, TPI 287, and its potential as a treatment for GBM as well as for future indications in metastatic tumors.
What This Means
Featuring: Moleculin Biotech
June 18, 2025
Walter Klemp, Founder, President, CEO and Chairman of Moleculin, discussed the Company’s recently announced positive FDA feedback received on the Pediatric Study Plan for Annamycin in children with relapsed/refractory acute myeloid leukemia (R/R AML).
What This Means
Featuring: SENTI Bio
June 18, 2025
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
What This Means
Featuring: Moleculin
June 11, 2025
Globally recognized Oncology Key Opinion Leader, Brian Andrew Van Tine, MD, PhD, discusses the positive topline results from the U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
What This Means
Featuring: Veru
May 28, 2025
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
What This Means
Featuring: Palisade Bio
May 27, 2025
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis
CEO Connect
Featuring: Autonomix Medical
May 13, 2025
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market
What This Means
Featuring: CNS Pharmaceuticals
May 13, 2025
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287|
Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM)
KOL Connect
Featuring: Veru
May 8, 2025
Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder of Veru
What This Means
Featuring: GRI Bio
May 8, 2025
Marc Hertz, President and CEO of GRI Bio discusses Interim Biomarker Data Demonstrating Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
What This Means
Featuring: Autonomix
May 1, 2025
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase (“POC 1”) where clinically meaningful pain reduction was demonstrated
Outlines Company’s plans to initiate market expansion study (“POC 2”) into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025
What This Means
Featuring: SENTI Bio
May 1, 2025
Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio discusses the positive data from lead program, SENTI-202, recently presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
KOL Connect
Featuring: SENTI Bio
April 21, 2025
Moderated discussion with Stephen Strickland, MD, MSCI, internationally respected leukemia researcher, Director of Leukemia Research for Sarah Cannon Research Institute and Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio.
Join Us
Sign up for email alerts to stay up-to-date on the latest Virtual Investor events
By submitting this form, you are consenting to receive marketing emails from: Virtual Investor. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact